Serum Brain Derived Neurotrophic Factor (BDNF) and cytokines in quetiapine treated psychosis

Serum BDNF and cytokines in quetiapine treated first episode psychosis.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000682943

Enrollment

Registered

2011-07-06

Start date

2004-06-01

Completion date

2009-06-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Psychosis in general and schizophrenia in particular are currently best understood as a group of illnesses whose symptoms are related to brain abnormalities that are the final common pathway from a multitude of aetiologies, due to the assorted interaction of specific genetic and environmental factors. The concept probably encompasses several primary disease processes (for example with a phospholipid, neurotrophin or autoimmune aetiology) that display a common endpoint in dopamine and other neurochemical abnormalities, and structural changes. While there has been a lot of research concerning the phospholipid hypothesis, there has been little around the neurotrophin and autoimmune aetiologies. We seek to determine BDNF and cytokine levels in the serum of 19 drug-naive subjects with psychosis, before and after treatment with quetiapine (an antipsychotic), as markers of neurotrophin activity and autoimmunity respectively, and compare with 19 age and sex matched healthy controls.

Interventions

We seek to determine BDNF and cytokine levels in the serum of 19 drug-naive subjects with psychosis, before and after three months of treatment with quetiapine (an antipsychotic), as markers of neurotrophin activity and autoimmunity respectively, and compare with 19 age and sex matched healthy controls. The serum samples are from 19 subjects recruited from a first-episode cohort treated for three months with quetiapine during a dose-finding study at Orygen Youth Health, Parkville, Vic (AU-SEA-00

Eligibility

Sex/Gender

All

Age

18 Years to 26 Years

Healthy volunteers

Inclusion criteria

For inclusion in the study patients must fulfil all of the following criteria: 1. Provision of written informed consent prior to any study specific procedures 2. A diagnosis of first-episode psychosis

Exclusion criteria

Any of the following is regarded as a criterion for exclusion from the study: 1. Subject returns form to withdraw consent

Outcome results